127. Frontotemporal lobar degeneration
[
44 clinical trials,
54 drugs（DrugBank:
21 drugs),
24 target genes / 46 target pathways ]
Searched query = "Frontotemporal lobar degeneration", "Frontotemporal dementia", "Semantic dementia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03987295 | September 27, 2019 | 4 November 2019 | A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients | A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia | Frontotemporal Dementia | Drug: AL001 | Alector Inc. | Recruiting | 18 Years | 80 Years | All | 32 | Phase 2 | United States;Canada;Germany;Italy;Netherlands;United Kingdom | |
| 2 | NCT04115384 | September 9, 2019 | 14 October 2019 | Intranasal Insulin in Frontotemporal Dementia (FTD) | A Single Center Feasibility Study of Intranasal Insulin in Frontotemporal Dementia NIFT-D | Frontotemporal Dementia, Behavioral Variant | Drug: Novolin-R insulin | HealthPartners Institute | Recruiting | 41 Years | 89 Years | All | 12 | Phase 2 | United States | |
| 3 | NCT03636204 | September 14, 2018 | 29 April 2019 | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin Mutation | A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation | Healthy;Frontotemporal Dementia | Biological: AL001;Other: Placebo | Alector Inc. | Recruiting | 18 Years | 80 Years | All | 60 | Phase 1 | United States;Canada;United Kingdom;Netherlands | |
| 4 | NCT03658135 | September 12, 2018 | 15 April 2019 | BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES | A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes | Primary Tauopathies;Corticobasal Degeneration Syndrome;Frontotemporal Lobar Degeneration With Tau Inclusions;MAPT Mutation Carriers, Symptomatic;Traumatic Encephalopathy Syndrome;Nonfluent Aphasia, Progressive | Drug: BIIB092;Other: Placebo | University of California, San Francisco | Recruiting | 35 Years | 80 Years | All | 32 | Phase 1 | United States | |
| 5 | NCT03260920 | January 31, 2018 | 11 February 2019 | Intranasal Oxytocin for Frontotemporal Dementia | A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia | Frontotemporal Dementia | Drug: Syntocinon | Lawson Health Research Institute | Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants | Recruiting | 30 Years | 80 Years | All | 112 | Phase 2 | United States;Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03625128 | January 2, 2018 | 28 October 2019 | 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls | Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment | Drug: F-18 | Chang Gung Memorial Hospital | Not recruiting | 20 Years | 90 Years | All | 36 | Early Phase 1 | Taiwan | |
| 7 | NCT02707978 | September 30, 2017 | 4 February 2019 | F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) | F 18 T807 Tau PET Imaging of Frontotemporal Dementia | Alzheimer Disease | Drug: F 18 T807 | Washington University School of Medicine | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | United States | |
| 8 | NCT03272230 | September 6, 2017 | 1 April 2019 | Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System | Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease | Apathy;Frontotemporal Dementia;Parkinson Disease;Depressive Symptoms | Behavioral: ECOCAPTURE;Behavioral: Cognitive and Behavioral experimental tasks;Diagnostic Test: Neuropsychological assessment;Behavioral: ICM_APATHY_TASKS;Other: MRI;Biological: Neurohormonal mechanisms;Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease | Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 40 Years | 85 Years | All | 135 | N/A | France | |
| 9 | NCT03545126 | August 21, 2017 | 7 October 2019 | Human CNS Tau Kinetics in Tauopathies | Human CNS Tau Kinetics in Tauopathies | Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD);Frontotemporal Dementia (FTD MAPT Mutation) | Other: 13C6 Leucine | Washington University School of Medicine | Association of Frontotemporal Degeneration;Tau Consortium | Recruiting | 18 Years | N/A | All | 32 | N/A | United States |
| 10 | NCT03174938 | May 15, 2017 | 11 June 2018 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03040713 | April 11, 2017 | 21 January 2019 | Flortaucipir PET Imaging in Subjects With FTD | 18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia | Frontotemporal Dementia | Drug: 18F-AV-1451;Drug: 18F-AV-45 | Avid Radiopharmaceuticals | Not recruiting | 18 Years | N/A | All | 14 | Phase 1 | United States | |
| 12 | EUCTR2017-000094-36-SE | 31/03/2017 | 22 May 2017 | The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders | The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders | Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: HLGT Classification code 10028037 Term: Movement disorders (incl parkinsonism) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10048598 Term: Cognitive disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1 Level: PT Classification code 10074616 Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-RO6958948 Pharmaceutical Form: Injection Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl Pharmaceutical Form: Injection | Skåne University Hospital | Authorised | Female: yes Male: yes | Phase 2 | Sweden | ||||
| 13 | NCT02862210 | January 27, 2017 | 26 August 2019 | Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia | Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia | Frontotemporal Dementia (FTD) | Drug: Lithium Carbonate;Drug: Placebo | Columbia University | Alzheimer’s Drug Discovery Foundation | Recruiting | 40 Years | 85 Years | All | 60 | Phase 2 | United States |
| 14 | EUCTR2015-005604-29-NL | 16/11/2016 | 2 October 2017 | Imaging of tau in patients with dementia | Tau-imaging in tauopathies; Alzheimer’s disease and non-AD dementias - TITAN | Dementia inducing Alzheimer's disease, Frontotemporal dementia (FTD) and Lewy Body Dementia (DLB) MedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10057095 Term: Diffuse Lewy body disease System Organ Class: 100000072901 MedDRA version: 20.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10012283 Term: Dementia due to other general medical conditions System Organ Class: 100000014717 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: 18F-AV-1451 Pharmaceutical Form: Solution for injection INN or Proposed INN: not applicable CAS Number: 152201-90-6 Current Sponsor code: 18F-Av-1451 Other descriptive name: T807 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 240- | VU University Medical Center | Authorised | Female: yes Male: yes | Phase 2 | Netherlands | ||||
| 15 | NCT02676843 | April 2016 | 8 April 2019 | Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations | Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations | Frontotemporal Lobar Degeneration;FTLD;Frontotemporal Dementia;FTD;Tauopathies | Drug: 18F-AV-1451 | Columbia University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 7 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2014-001315-40-IT | 03/12/2014 | 11 April 2016 | Florbetapir-PET scan in subjects with a known mutation for autosomal dominant Alzheimer's Disease taking part in the ItalianDIAfN study | Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)” - Amyloid-PET in ItalianDIAfN | Autosomal Dominant Alzheimer's Disease MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Amyvid Product Name: Florbetapir (18F) Product Code: Florbetapir (18F) Pharmaceutical Form: Injection INN or Proposed INN: florbetapir (18F) CAS Number: 956103-76-7 Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 370- | IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli | Authorised | Female: yes Male: yes | Italy | |||||
| 17 | EUCTR2014-002013-37-GB | 06/10/2014 | 8 August 2016 | An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trial | An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia | Alzheimer’s Disease and behavioral variant Frontotemporal Dementia MedDRA version: 19.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Leuco-methylthioninium bis(hydromethanesulfonate) Product Code: LMTM/TRx0237 Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: 1236208-20-0 Current Sponsor code: TRx0237 Other descriptive name: N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- | TauRx Therapeutics Ltd | Authorised | Female: yes Male: yes | 966 | Phase 3 | United States;Taiwan;Finland;Spain;Russian Federation;United Kingdom;France;Canada;Malaysia;Belgium;Singapore;Romania;Croatia;Australia;Bulgaria;Netherlands;Germany;Korea, Republic of | |||
| 18 | NCT02149160 | October 2014 | 11 April 2016 | Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation | Granulin Mutation | Drug: FRM-0334;Drug: Placebo | FORUM Pharmaceuticals Inc | Not recruiting | 21 Years | 75 Years | Both | 30 | Phase 2 | United States;Belgium;France;Italy;Netherlands;United Kingdom | |
| 19 | EUCTR2014-000422-38-SE | 19/09/2014 | 7 October 2014 | A study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of the protein tau | An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau | Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnostic conditions. MedDRA version: 17.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10053643 Term: Neurodegenerative disorder System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: LLT Classification code 10012285 Term: Dementia due to Pick's disease System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10012267 Term: Dementia System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10067889 Term: Dementia with Lewy bodies System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.0 Level: PT Classification code 10036813 Term: Progressive supranuclear palsy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-AV-1451 Pharmaceutical Form: Injection | Skåne University Hospital, Region Skåne | Authorised | Female: yes Male: yes | Sweden | |||||
| 20 | NCT02245568 | August 2014 | 11 June 2018 | Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) | An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) | Alzheimer's Disease;Behavioral Variant Frontotemporal Dementia | Drug: TRx0237 | TauRx Therapeutics Ltd | Not recruiting | N/A | N/A | All | 913 | Phase 3 | United States;Australia;Belgium;Canada;Croatia;Finland;France;Germany;Korea, Republic of;Malaysia;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;Argentina;Bulgaria;Italy;Poland;Romania | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT01937013 | September 12, 2013 | 20 August 2018 | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Frontotemporal Dementia | Drug: Intranasal oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | Canadian Institutes of Health Research (CIHR) | Not recruiting | 30 Years | 85 Years | All | 52 | Phase 2 | Canada |
| 22 | NCT01626378 | May 2013 | 11 June 2018 | Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) | A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) | Behavioral Variant Frontotemporal Dementia (bvFTD) | Drug: TRx0237;Drug: Placebo | TauRx Therapeutics Ltd | Not recruiting | N/A | 79 Years | All | 220 | Phase 3 | United States;Australia;Canada;Croatia;Germany;Italy;Netherlands;Poland;Romania;Singapore;Spain;United Kingdom;Argentina;Bulgaria;Finland | |
| 23 | EUCTR2012-004328-40-IT | 01/03/2013 | 27 January 2014 | study of neuroinflammation in pathologies like Alzheimer, mild cognitive impairment, dementia and SLA | IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES | mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA MedDRA version: 14.1 Level: LLT Classification code 10050727 Term: RI scan System Organ Class: 100000004848 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: NA Product Code: (R)-[N-metil-11C1-PK11195(PK) Pharmaceutical Form: Solution for injection Current Sponsor code: (R)-[N-metil-11C]-PK11195 Concentration unit: MBq megabecquerel(s) Concentration type: up to Concentration number: 185- | OSPEDALE S. RAFFAELE DI MILANO | Authorised | Female: yes Male: yes | Italy | |||||
| 24 | EUCTR2011-005529-34-GB | 17/01/2013 | 28 September 2015 | A comparison study of LMTM and placebo in patients with behavioral variant frontotemporal dementia | A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) - TRx-237-007 | behavioral variant Frontotemporal Dementia (bvFTD) MedDRA version: 18.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Leuco-methylthioninium bis(hydromethanesulfonate) Product Code: LMTM/TRx0237 Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: 1236208-20-0 Current Sponsor code: TRx0237 Other descriptive name: N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | TauRx Therapeutics Ltd | Authorised | Female: yes Male: yes | 180 | United States;Finland;Spain;United Kingdom;Italy;Canada;Poland;Singapore;Croatia;Romania;Australia;Germany;Netherlands | ||||
| 25 | EUCTR2011-005529-34-DE | 28/12/2012 | 30 May 2016 | A comparison study of LMTM and placebo in patients with behavioral variant frontotemporal dementia | A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) - TRx-237-007 | behavioral variant Frontotemporal Dementia (bvFTD) MedDRA version: 18.1 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Leuco-methylthioninium bis(hydromethanesulfonate) Product Code: LMTM/TRx0237 Pharmaceutical Form: Tablet INN or Proposed INN: N/A CAS Number: 1236208-20-0 Current Sponsor code: TRx0237 Other descriptive name: N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | TauRx Therapeutics Ltd | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Finland;Spain;United Kingdom;Italy;Canada;Poland;Singapore;Croatia;Romania;Australia;Germany;Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2011-004571-37-IT | 21/02/2012 | 23 May 2012 | Amiodarone therapy for treatment of fontotemporat dementia caused by progranulin deficiency | - Rescue of Progranulin HaploInsufficiency in Frontotemporal Dementia - ReProIn-FTD | frontotemporal dementia associated to progranulin deficit MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Pharmaceutical Form: Tablet INN or Proposed INN: AMIODARONE CAS Number: 1951-25-3 Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | Authorised | Female: yes Male: yes | Italy | |||||
| 27 | NCT00604591 | July 2011 | 26 August 2019 | Effects of Tolcapone on Frontotemporal Dementia | Investigation of the Dopamine System in Frontotemporal Dementia | Frontotemporal Lobar Degeneration | Drug: Tolcapone;Drug: Placebo | Columbia University | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 40 Years | 85 Years | All | 28 | Phase 2 | United States |
| 28 | NCT01386333 | June 2011 | 19 February 2015 | Safety Study of Intranasal Oxytocin in Frontotemporal Dementia | A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF | Frontotemporal Dementia | Drug: oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | The Consortium of Canadian Centres for Clinical Cognitive Research (C5R) | Not recruiting | 30 Years | 80 Years | Both | 23 | Phase 1 | Canada |
| 29 | JPRN-UMIN000003683 | 2010/06/01 | 2 April 2019 | The efficacy of ferulic acid in the treatment of dementia | Alzheimer's Disease, Dementia of Lewy Body,Vascular Dementia, Frontotemporal Dementia | Taking of Ferulic Acid for 6 months followed by Not taking of Ferulic Acid for 6 months. Not taking of Ferulic Acid for 6 months followed by taking of Ferulic Acid for 6 months. | Shimane University Hospital | Not Recruiting | 20years-old | 90years-old | Male and Female | 50 | Not selected | Japan | ||
| 30 | NCT01623284 | March 2010 | 4 January 2016 | PiB PET Scanning in Speech and Language Based Dementias | PiB PET Scanning in Speech and Language Based Dementias | PPA;Primary Progressive Aphasia;Aphasia;Non-fluent Aphasia;Semantic Dementia;Apraxia of Speech;Primary Progressive Nonfluent Aphasia;Progressive Aphasia | Drug: C-11 PiB;Drug: F-18 FDG | Mayo Clinic | Not recruiting | 18 Years | N/A | Both | 168 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01056965 | January 2010 | 15 April 2019 | Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies | Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia | Drug: davunetide (AL-108, NAP);Drug: Placebo nasal spray | University of California, San Francisco | Not recruiting | 40 Years | 85 Years | All | 12 | Phase 1 | United States | |
| 32 | NCT01002300 | September 2009 | 19 February 2015 | Oxytocin and Social Cognition in Frontotemporal Dementia | Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia | Frontotemporal Dementia;Pick's Disease | Drug: intranasal oxytocin | Lawson Health Research Institute | The Alzheimer Society London and Middlesex | Not recruiting | 30 Years | 80 Years | Both | 24 | N/A | Canada |
| 33 | NCT01890343 | September 2009 | 19 October 2017 | Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. | A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. | Alzheimer's Disease;Frontotemporal Dementia | Drug: florbetapir 18F;Drug: 18F-FDG | Avid Radiopharmaceuticals | Not recruiting | 45 Years | N/A | All | 34 | Phase 2 | United Kingdom | |
| 34 | EUCTR2008-003597-18-GB | 28/05/2009 | 19 March 2012 | Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteers | A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls | Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease. MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - Investigations | Product Name: florbetapir 18F Product Code: 18F-AV-45 Pharmaceutical Form: Injection CAS Number: 956103-76-7 Current Sponsor code: 18F-AV-45 Other descriptive name: florbetapir 18F Injection Concentration unit: MBq/µl megabecquerel(s)/microlitre Concentration type: not less then Concentration number: 54- | Avid Radiopharmaceuticals, Inc | Authorised | Female: yes Male: yes | 40 | United Kingdom | ||||
| 35 | NCT00950430 | April 2008 | 14 October 2019 | Imaging of Brain Amyloid Plaques in the Aging Population | Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia | Alzheimer's Disease;Dementia With Lewy Bodies;Frontotemporal Dementia;Vascular Dementia | Drug: Pittsburgh Compound B (C-11 PiB);Drug: F-18 FDG;Drug: Tau (18-F-AV-1451) | Mayo Clinic | National Institute on Aging (NIA) | Recruiting | 30 Years | 100 Years | All | 2500 | Phase 4 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | JPRN-UMIN000003239 | 2008/01/01 | 2 April 2019 | Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementia | Frontotemporal dementia | Discontinuation of donepezil | National Hospital Organization Kikuchi Hospital | Not Recruiting | 50years-old | 90years-old | Male and Female | 25 | Not selected | Japan | ||
| 37 | NCT00545974 | October 2007 | 22 October 2019 | Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia | A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia | Frontal Lobe Dementia;Frontotemporal Lobe Dementia;Semantic Dementia | Drug: memantine;Drug: Placebo pill | University of California, San Francisco | Forest Laboratories | Not recruiting | 40 Years | 80 Years | All | 81 | Phase 4 | United States |
| 38 | NCT00594737 | October 2007 | 19 February 2015 | Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia | An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia | Frontotemporal Dementia | Drug: memantine hydrochloride | Tiffany Chow, MD | H. Lundbeck A/S | Not recruiting | 40 Years | 80 Years | Both | 17 | Phase 3 | Canada |
| 39 | NCT00376051 | September 2006 | 16 December 2017 | Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia | Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia | Frontotemporal Dementia | Drug: Citalopram | Sunnybrook Health Sciences Centre | Alzheimer Society of Canada | Not recruiting | 18 Years | N/A | All | 22 | Phase 4 | Canada |
| 40 | EUCTR2005-005915-13-GB | 12/07/2006 | 14 August 2012 | An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromes | An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromes | Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potential for slowing the disease process as well as providing symptomatic improvement in hitherto untreatable, ultimately fatal conditions. MedDRA version: 8.1 Level: PT Classification code 10012267 | Product Name: Methylthioninium chloride Product Code: MTC TRx0014-001 capsules Pharmaceutical Form: Capsule, hard Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100 - | TauRx Therapeutics PTE Ltd | Authorised | Female: yes Male: yes | 20 | United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT00127114 | September 2005 | 16 December 2017 | Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) | Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) | Dementia | Drug: Amantadine;Drug: Placebo | Johns Hopkins University | Not recruiting | 40 Years | 90 Years | All | 0 | Phase 4 | United States | |
| 42 | NCT00200538 | September 2005 | 19 February 2015 | Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients | Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients | Dementia | Drug: memantine | Nantes University Hospital | Not recruiting | 45 Years | 75 Years | Both | 52 | Phase 2 | France | |
| 43 | NCT00187525 | May 2004 | 19 February 2015 | A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration | Frontotemporal Lobar Degeneration | Drug: Memantine | University of California, San Francisco | Forest Laboratories | Not recruiting | 40 Years | 80 Years | Both | Phase 4 | |||
| 44 | NCT00416169 | May 2003 | 19 February 2015 | A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia | An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex | Frontotemporal Dementia;Pick Complex | Drug: galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Not recruiting | 30 Years | 80 Years | Both | 41 | Phase 2 |